Novo Nordisk A/S $NVO Shares Sold by Cerity Partners LLC

Cerity Partners LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 34.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 558,615 shares of the company’s stock after selling 295,607 shares during the period. Cerity Partners LLC’s holdings in Novo Nordisk A/S were worth $30,450,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. State of Wyoming acquired a new stake in Novo Nordisk A/S in the first quarter worth $38,000. AQR Capital Management LLC increased its position in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Novo Nordisk A/S by 1.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 96,487 shares of the company’s stock valued at $6,700,000 after buying an additional 1,407 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at $3,157,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO opened at $57.34 on Friday. The business has a 50 day moving average price of $49.47 and a two-hundred day moving average price of $55.47. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The company has a market capitalization of $256.02 billion, a price-to-earnings ratio of 16.67 and a beta of 0.66. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NVO. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.